TCGA-UY-A9PB-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 29.53350854
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- COMPLEMENT+0.460
- DNA_REPAIR+0.440
- INFLAMMATORY_RESPONSE+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
- IL6_JAK_STAT3_SIGNALING+0.410
- MYC_TARGETS_V1+0.410
Top 10 suppressed
- KRAS_SIGNALING_DN-0.350
- SPERMATOGENESIS-0.310
- PANCREAS_BETA_CELLS-0.270
- BILE_ACID_METABOLISM-0.200
- PEROXISOME-0.180
- ESTROGEN_RESPONSE_EARLY-0.140
- ESTROGEN_RESPONSE_LATE-0.080
- ADIPOGENESIS-0.070
- FATTY_ACID_METABOLISM-0.070
- MYOGENESIS-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.941 |
| 2 | SRR934722 | — | — | 0.941 |
| 3 | SRR934864 | — | — | 0.940 |
| 4 | TCGA-4Z-AA86-01A-11R-A39I-07 | — | — | 0.939 |
| 5 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.937 |
| 6 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.937 |
| 7 | 62966348-1C16-4A6D-AA82-707B3F759D5C | — | — | 0.936 |
| 8 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.933 |
| 9 | SRR934874 | — | — | 0.925 |
| 10 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.440 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |